Apr 16, 09:08
AnnouncementsLupin receives FDA approval for Generic Actos tablets
AnnouncementsLupin acquires Laboratorios Grin S.A. De C.V., Mexico
AnnouncementsLupin launches Generic Niaspan tablets in US
100% of moneycontrol users recommend buying Lupin. What's your call on Lupin today? Read 12 investor views
|Company Name||Last Price||%
|Dr Reddys Labs||2541.20||-1.41||2939.80||1901.00||43,228.07|
|Mar' 14||Dec' 13||Sep' 13||Jun' 13|
Lupin is in the Pharmaceuticals sector. The current market capitalisation stands at Rs 42,192.16 crore.The company has reported a consolidated sales of Rs 2,982.97 crore and a Net Profit of Rs 483.74 crore for the quarter ended Dec 2013.
The company management includes Desh Bandhu Gupta - Chairman, Kamal K Sharma - Managing Director, M D Gupta - Executive Director, Nilesh Gupta - Executive Director, Vinita Gupta - Director, Vijay Kelkar - Director, Richard Zahn - Director, R A Shah - Director, K U Mada - Director, Dileep C Choksi - Additional Director.
It is listed on the BSE with a BSE Code of 500257 and the NSE with an NSE Code of LUPIN.
Its Registered office is at 159, C.S.T Road, Kalina,,Santacruz (E) Mumbai,Maharashtra - 400098.